Figure 4

Synergy of CMAP-identified drugs with DEX in T-ALL cell lines. Graphs show cell survival following 48 h incubation. Comparisons were made in each data set to the respective control condition, which was set to 100%. Vehicle control (C) and the following drug treatments were analysed (A) 10 nM (R10), 25 nM (R25), 50 nM (R50) rapamycin and 1 μ M DEX (D1) in ALL-SIL; (B) 1 μ M (D1), 10 μ M (D10), 500 μ M (D500) DEX and 50 nM rapamycin (R50) in CEM; (C) 10 μ M (L10), 20 μ M (L20) LY294002 and 1 μ M DEX (D1) in ALL-SIL; (D) 10 μ M (Q10), 25 μ M (Q25) quercetin and 1 μ M DEX (D1) in ALL-SIL; (E) 10 μ M (R10), 50 μ M (R50), 100 μ M (R100) resveratrol and 1 μ M DEX (D1) in ALL-SIL; ^*P<0.05, ^**P<0.01 (repeated measures ANOVA). Data represent the mean of 4–5 experiments measured in triplicate (±s.e.m.).